KR

Kirtida Radhakrishna Desai

Active Director Director DIN 06953567
DIN 06953567 First appointment Nov 2014 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 2 historical roles
Total affiliations 6 Since Nov 2014
Shareholding value •••• Premium profile

About Kirtida Radhakrishna Desai

Data last updated:

Kirtida Radhakrishna Desai is a Director at Vivatest Lifescience Private Limited (since 2022), Director at Vivatest Research And Development Private Limited (since 2014) and Designated Partner at Respir Labs Llp (since 2025), and holds 1 more current directorship. The companies operate in Chemicals, Pharma and Business Services. The 2 current companies with reported revenue have a combined latest revenue of ₹3.94 Cr; the largest is Vivatest Lifescience Private Limited at ₹2.28 Cr (FY 2024). Earlier, Kirtida Radhakrishna Desai was a Partner at Delnova Healthcare Llp (2017–2018) and Designated Partner at Kireshwar Traders Llp (2016–2017).

DIN 06953567
Primary Designation Director
Industry Chemicals
First Appointment 25 Nov 2014
Oldest Company Age 11 yrs
Largest company Vivatest Lifescience Private Limited · ₹2.28 Cr (FY 2024)
Combined revenue ₹3.94 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Vivatest Lifescience Private Limited U24230MH2022PTC381745
Director29 Apr 20222022₹2.28 Cr (FY 2024)Active
Director25 Nov 20142014₹1.67 Cr (FY 2024)Active
Respir Labs Llp ACT-4867
Designated Partner15 Dec 20252025Active
Designated Partner30 Dec 20242024Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Partner10 Oct 20172017₹5.74 Cr (FY 2023)Active
Designated Partner25 Jan 20162014Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Kirtida Radhakrishna Desai

Directorship timeline

Open interactive timeline →
Vivatest Lifescience Private Limited
Vivatest Research And Development Private Limited
Respir Labs Llp
Ark Pharmacode Llp
Premium access

Shareholding and investment profile for Kirtida Radhakrishna Desai

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kirtida Radhakrishna Desai

Kirtida Radhakrishna Desai currently holds 4 directorships: Vivatest Lifescience Private Limited (Director, since 29 Apr 2022, revenue ₹2.28 Cr (FY 2024)); Vivatest Research And Development Private Limited (Director, since 25 Nov 2014, revenue ₹1.67 Cr (FY 2024)); Respir Labs Llp (Designated Partner, since 15 Dec 2025); Ark Pharmacode Llp (Designated Partner, since 30 Dec 2024).

Kirtida Radhakrishna Desai was first appointed on 25 Nov 2014 as Director at Vivatest Research And Development Private Limited. The most recent appointment on record is 15 Dec 2025 at Respir Labs Llp.

The 2 current companies of Kirtida Radhakrishna Desai that report revenue have a combined latest revenue of ₹3.94 Cr: Vivatest Lifescience Private Limited ₹2.28 Cr (FY 2024); Vivatest Research And Development Private Limited ₹1.67 Cr (FY 2024).

Kirtida Radhakrishna Desai held 2 earlier board appointments: Delnova Healthcare Llp (Partner, 10 Oct 2017 to 29 Sep 2018); Kireshwar Traders Llp (Designated Partner, 25 Jan 2016 to 18 Aug 2017).

The current boards of Kirtida Radhakrishna Desai's companies include Analesh Anand Desai (Vivatest Lifescience Private Limited), Geeta Radhakrishna Desai (Vivatest Research And Development Private Limited), Tanvi Tushar Gaikar (Respir Labs Llp), Arati Anand Desai (Ark Pharmacode Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available